A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending, Multidose Study to Evaluate the Safety and Efficacy of Linaclotide in Pediatric Participants (Age 2 to 5 Years) With Functional Constipation
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Linaclotide (Primary)
- Indications Constipation
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie; Allergan
Most Recent Events
- 01 Sep 2024 Results(n=34) evaluating the dose-response, safety, and efficacy of 4 weeks of linaclotide compared with placebo in children 2-5 years of age with functional constipation , published in the Journal of Pediatric Gastroenterology and Nutrition
- 09 May 2022 According to an Ironwood Pharmaceuticals media release, data from this study will be presented at the Digestive Disease WeekCarlo Di Lorenzo, M.D., Nationwide Children's Hospital. (DDW) 2022 meeting by
- 11 May 2021 Status changed from active, no longer recruiting to completed.